Evaluation of MIF -173 G/C Polymorphism in Turkish Patients with Ankylosing Spondylitis

Yıl 2016, Cilt: 33 Sayı: 6, 614 - 619, 01.11.2016

Çevik Gürel Ahmet İnanır Ayşe Feyda Nursal Akın Tekcan Aydın Rüstemoğlu Serbülent Yiğit

Öz

Background: Ankylosing spondylitis (AS) is a chronic inflammatory disease mainly affecting the spine and sacroiliac joints. Macrophage migration inhibitory (MIF) factor is a regulatory cytokine that inhibits random immune cell migration. MIF gene promoter polymorphisms play a role in the progression of several inflammatory disorders. Aims: To investigate the relationship between the MIF gene -173 G/C single-nucleotide polymorphism (SNP) and AS. Study Design: Cross-sectional study. Methods: In this study, a total of 161 AS and 194 normal controls were recruited. The MIF gene -173 G/C SNP was analyzed by polymerase chain reaction using the restriction fragment length polymorphism method.  Results: There was no significant difference between groups in terms of genotype distribution (p>0.05). When wild-type G/G and G/C+C/C genotypes are compared in terms of clinical characteristics, there is a significant difference between the average age and the duration of disease in AS patients (p<0.05).  Conclusion: No significant relationship between AS disease and MIF -173 G/C polymorphism was found. MIF -173 G/C polymorphism (C allele) may affect the time of onset and the duration of disease in AS patients.

Anahtar Kelimeler

Ankylosing spondylitis, macrophage migration inhibitory factor, polymorphism

Kaynakça

• 1. Daikh DI, Chen PP. Advances in managing ankylosing spondylitis. F1000Prime Rep 2014;6:78. [CrossRef]
• 2. Tsui FW, Tsui HW, Akram A, Haroon N, Inman RD. The genetic basis of ankylosing spondylitis: new insights into disease pathogenesis. Appl Clin Genet 2014;7:105-15. [CrossRef]
• 3. Yigit S, Inanir A, Tural S, Filiz B, Tekcan A. The effect of IL-4 and MTHFR gene variants in ankylosing spondylitis. Z Rheumatol 2015;1:60-6. [CrossRef]
• 4. Smith JA. Update on ankylosing spondylitis: current concepts in pathogenesis. Curr Allergy Asthma Rep 2015;15:489. [CrossRef]
• 5. Falvey JD, Bentley RW, Merriman TR, Hampton MB, Barclay ML, Gearry RB, et al. Macrophage migration inhibitory factor gene polymorphisms in inflammatory bowel disease: an association study in New Zealand Caucasians and meta-analysis. World J Gastroenterol 2013;19:6656-64. [CrossRef]
• 6. Renner P, Roger T, Calandra T. Macrophage migration inhibitory factor: gene polymorphisms and susceptibility to inflammatory diseases. Clin Infect Dis 2005;41:513-9. [CrossRef]
• 7. Kozaci LD, Sari I, Alacacioglu A, Akar S, Akkoc N. Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for macrophage migration inhibitory factor. Mod Rheumatol 2010;20:34-9. [CrossRef]
• 8. Park SH, Choe JY, Kim SK, Lee H, Castrejón I, Pincus T. Routine assessment of Patient Index Data (RAPID3) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores yield similar information in 85 Korean patients with Ankylosing Spondylitis seen in usual clinical care. J Clin Rheumatol 2015;21:300-4. [CrossRef]
• 9. Makhija R, Kingsnorth A, Demaine A. Gene polymorphisms of the macrophage migration inhibitory factor and acute pancreatitis. JOP 2007;8:289-95.
• 10. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version. Availabe from: www.OpenEpi.com (accessed 2015/09/17).
• 11. Donn RP, Shelley E, Ollier WE, Thomson W, British Pediatric Rheumatology Study Group. A novel 5’-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2001;44:1782-5. [CrossRef]
• 12. Donn R, Alourfi Z, De Benedetti F, Meazza C, Zeggini E, Lunt M, et al. Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum 2002;46:2402-9. [CrossRef]
• 13. Radstake TR, Sweep FC, Welsing P, Franke B, Vermeulen SH, Geurts-Moespot A, et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 2005;52:3020-9. [CrossRef]
• 14. De Benedetti F, Meazza C, Vivarelli M, Rossi F, Pistorio A, Lamb R, et al. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2003;48:1398-407. [CrossRef]
• 15. Liu R, Xu N, Wang X, Shen L, Zhao G, Zhang H, et al. Influence of MIF, CD40, and CD226 polymorphisms on risk of rheumatoid arthritis. Mol Biol Rep 2012;39:6915-22. [CrossRef]
• 16. Llamas-Covarrubias MA, Valle Y, Bucala R, Navarro-Hernández RE, Palafox-Sánchez CA, Padilla-Gutiérrez JR, et al. Macrophage migration inhibitory factor (MIF): genetic evidence for participation in early onset and early stage rheumatoid arthritis. Cytokine 2013;61:759-65. [CrossRef]
• 17. Barton A, Lamb R, Symmons D, Silman A, Thomson W, Worthington J, et al. Macrophage migration inhibitory factor (MIF) gene polymorphism is associated with susceptibility to but not severity of inflammatory polyarthritis. Genes Immun 2003;4:487-91. [CrossRef]
• 18. Martínez A, Orozco G, Varadé J, Sánchez López M, Pascual D, Balsa A, et al. Macrophage migration inhibitory factor gene: influence on rheumatoid arthritis susceptibility. Hum Immunol 2007;68:744-7. [CrossRef]
• 19. Fei BY, Lv HX, Yang JM, Ye ZY. Association of MIF-173 gene polymorphism with inflammatory bowel disease in Chinese Han population. Cytokine 2008;41:44-7. [CrossRef]
• 20. Nohara H, Okayama N, Inoue N, Koike Y, Fujimura K, Suehiro Y, et al. Association of the -173 G/C polymorphism of the macrophage migration inhibitory factor gene with ulcerative colitis. J Gastroenterol 2004;39:242-6. [CrossRef]
• 21. Przybyłowska K, Mrowicki J, Sygut A, Narbutt P, Dziki Ł, Dziki A, et al. Contribution of the -173 G/C polymorphism of macrophage migration inhibitory factor gene to the risk of inflammatory bowel diseases. Pol Przegl Chir 2011;83:76-80. [CrossRef]
• 22. Gunal EK, Sarvan FO, Kamali S, Gul A, Inanc M, Carin M, et al. Low frequency of HLA-B27 in ankylosing spondylitis patients from Turkey. Joint Bone Spine 2008;75:299-302. [CrossRef]
• 23. Cinar M, Akar H, Yilmaz S, Simsek I, Karkucak M, Sagkan RI, et al. A polymorphism in ERAP1 is associated with susceptibility to ankylosing spondylitis in a Turkish population. Rheumatol Int 2013;33:2851-8. [CrossRef]
• 24. Wu J, Fu S, Ren X, Jin Y, Huang X, Zhang X, et al. Association of MIF promoter polymorphisms with childhood asthma in a northeastern Chinese population. Tissue Antigens 2009;73:302- 6. [CrossRef]
• 25. Donn RP, Plant D, Jury F, Richards HL, Worthington J, Ray DW, et al. Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. J Invest Dermatol 2004;123:484-7. [CrossRef]
• 26. Amoli MM, Donn RP, Thomson W, Hajeer AH, Garcia-Porrua C, Lueiro M, et al. Macrophage migration inhibitory factor gene polymorphism is associated with sarcoidosis in biopsy proven erythema nodosum. J Rheumatol 2002;29:1671-3.
• 27. Sánchez E, Gómez LM, Lopez-Nevot MA, González-Gay MA, Sabio JM, Ortego-Centeno N, et al. Evidence of association of macrophage migration inhibitory factor gene polymorphisms with systemic lupus erythematosus. Genes Immun 2006;7:433-6. [CrossRef]
• 28. Wang FF, Huang XF, Shen N, Leng L, Bucala R, Chen SL, et al. A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still’s disease. Arthritis Res Ther 2013;15:65. [CrossRef]
• 29. Nalbantoglu S, Tabel Y, Mir S, Berdeli A. Lack of association between macrophage migration inhibitory factor gene promoter (-173 G/C) polymorphism and childhood HenochSchönlein purpura in Turkish patients. Cytokine 2013;62:160- 4. [CrossRef]
• 30. Amoli MM, Martin J, Miranda-Filloy JA, Garcia-Porrua C, Ollier WE, Gonzalez-Gay MA. Lack of association between macrophage migration inhibitory factor gene (-173 G/C) polymorphism a